Alzheimer's Disease and Related Dementias (ADRD) Prevalence in American Samoa

American Samoa Community Cancer Coalition

Status: Enrolling

Conditions: Alzheimer's Disease and Related Dementia

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT05924529

ASCCC0191792

Details and patient eligibility

About

The goal of this study is to learn about ADRD prevalence within the Samoan population. Participants will be administered a series of cognitive assessments to determine cognitive status and a population-based prevalence of Mild Cognitive Impairment (MCI) and ADRD. Blood samples will also be collected from the participants for genetic and plasma biomarker analysis.

Full description

This study aims to do the following:

Test ADRD knowledge, health literacy, research readiness and determine ADRD resilience and vulnerability factors, and cognitive status in a probability sample of 981 Samoans age 50+ using culturally adapted instruments in our probability sample.

Conduct Gold Standard evaluations in our probability sample using the Uniform Data Set (UDSv3.0) from the National Institute on Aging (NIA) Alzheimer's Disease Research Center program to determine a population-based prevalence of MCI and ADRD for harmonization, data sharing, and comparison to other groups, and,

Cross-validate Gold Standard dementia evaluations with genetic (i.e., ApoE) and plasma Amyloid-Tau-Neuronal Injury/Neurodegeneration (ATN) framework biomarkers in our probability sample and compare to information available for other racial/ethnic groups.

Enrollment: 1,098 estimated patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 50 or older
• Community dwelling
• Speaks English or Samoan
• Willing to contribute a biomarker specimen

Exclusion criteria

• Residing in Assistant Living or Skilled Nursing Facility
• Axis 1 Psychiatric diagnosis (e.g., Schizophrenia, Bipolar)
• Unstable medical condition (i.e., metastatic cancer) that could preclude completion of study visit

Trial design

1,098 participants in 1 patient group

Samoans in American Samoa

Description:

Cognitive assessments will be administered to all participants to assess cognitive status. Gold standard evaluations will be administered to cross-validate the results of the cognitive assessments. Blood will be extracted from all participants to cross-validate results from the prior cognitive assessments and Gold Standard evaluations and conduct plasma and genetic analysis.